Is MTST or GBDC a better dividend investment in 2026?

MTST currently yields 333333.33% with a 5% 5-year dividend growth rate. GBDC yields 11.86% with 5% growth. The better choice depends on your goal: MTST offers higher current income.

What is the dividend yield difference between MTST and GBDC?

MTST has a forward dividend yield of 333333.33% ($2.00/share annually). GBDC yields 11.86% ($1.50/share annually). The yield gap is 333321.47 percentage points.

Home › Compare › MTST vs GBDC

MTST vs GBDC: Dividend Comparison 2026

MTST yields 333333.33% · GBDC yields 11.86%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 MTST wins by $8.099219044190773e+31M in total portfolio value

INVESTMENT

TIME HORIZON10 years

MTST

● Live price

333333.33%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$8.099219044190773e+31M

Annual income

$80,944,421,463,343,720,000,000,000,000,000,000,000.00

Full MTST calculator →

GBDC

● Live price

11.86%

Share price

$12.65

Annual div

$1.50

5Y div CAGR

51.1%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.85M

Annual income

$16,450,733.83

Full GBDC calculator →

Portfolio growth — MTST vs GBDC

📍 MTST pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	MTST	GBDC
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, MTST + GBDC cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

MTST pays

GBDC pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTST

Annual income on $10K today (after 15% tax)

$28,333,333.33/yr

After 10yr DRIP, annual income (after tax)

$68,802,758,243,842,160,000,000,000,000,000,000,000.00/yr

GBDC

Annual income on $10K today (after 15% tax)

$1,007.91/yr

After 10yr DRIP, annual income (after tax)

$13,983,123.76/yr

At 15% tax rate, MTST beats the other by $68,802,758,243,842,160,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTST + GBDC for your $10,000?

MTST: 50%GBDC: 50%

100% GBDC50/50100% MTST

Portfolio after 10yr

$4.0496095220953863e+31M

Annual income

$40,472,210,731,671,860,000,000,000,000,000,000,000.00/yr

Blended yield

99.94%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

MTST

No analyst data

Altman Z

-75.5

Piotroski

2/9

GBDC

Analyst Ratings

Buy

Hold

Consensus: Buy

Price Target

$14.00

+10.7% upside vs current

Range: $13.00 — $15.00

Altman Z

0.6

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTST buys

GBDC buys

No recent congressional trades found for MTST or GBDC in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricMTSTGBDC

Forward yield	333333.33% ✓	11.86%
Annual dividend / share	$2.00 ✓	$1.50
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	51.1% ✓
Portfolio after 10y	$8.099219044190773e+31M	$20.85M ✓
Annual income after 10y	$80,944,421,463,343,720,000,000,000,000,000,000,000.00 ✓	$16,450,733.83
Total dividends collected	$8.098906375781879e+31M	$20.43M ✓
Payment frequency	quarterly	quarterly
Sector	Stock	BDC

Year-by-year: MTST vs GBDC ($10,000, DRIP)

Year	MTST Portfolio	MTST Income/yr	GBDC Portfolio	GBDC Income/yr	Gap
1← crossover	$33,344,033	$33,333,333.33	$12,492	$1,791.70	+$33.33M → MTST
2	$103,911,171,366	$103,875,493,250.26	$16,527	$3,160.58	+$103911.15M → MTST
3	$302,644,656,190,810	$302,533,471,237,448.00	$23,588	$5,904.90	+$302644656.17M → MTST
4	$823,817,797,451,856,400	$823,493,967,669,732,100.00	$37,141	$11,901.65	+$823817797451.82M → MTST
5	$2,095,836,995,961,804,000,000	$2,094,955,510,918,530,000,000.00	$66,205	$26,463.38	+$2095836995961804.00M → MTST
6	$4,983,251,920,823,462,000,000,000	$4,981,009,375,237,783,000,000,000.00	$137,452	$66,612.65	+$4983251920823461888.00M → MTST
7	$11,073,835,968,753,321,000,000,000,000	$11,068,503,889,198,040,000,000,000,000.00	$342,372	$195,298.53	+$1.1073835968753322e+22M → MTST
8	$22,999,277,308,531,336,000,000,000,000,000	$22,987,428,304,044,770,000,000,000,000,000.00	$1,053,292	$686,954.33	+$2.2999277308531335e+25M → MTST
9	$44,643,905,199,991,210,000,000,000,000,000,000	$44,619,295,973,271,085,000,000,000,000,000,000.00	$4,111,439	$2,984,416.95	+$4.464390519999121e+28M → MTST
10	$80,992,190,441,907,720,000,000,000,000,000,000,000	$80,944,421,463,343,720,000,000,000,000,000,000,000.00	$20,849,974	$16,450,733.83	+$8.099219044190773e+31M → MTST

MTST vs GBDC: Complete Analysis 2026

MTST — Stock

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.

Full MTST Calculator →

GBDC — BDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →

📬

Get this MTST vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTST vs SCHD MTST vs JEPI MTST vs O MTST vs KO MTST vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.